Transitioning From Discovery to Lead Optimization: Peptide Synthesis Applications in Modern Peptide Drug Development

Life Sciences, Drug Discovery & Development, Fundamental Research,
  • Tuesday, July 30, 2024 | 10am EDT (NA) / 3pm BST (UK) / 4pm CEST (EU-Central)
  • 60 min

Webinar Preview

Discover an informative webinar providing insights into the pivotal role of peptide synthesis in modern drug development.

Peptides have become crucial in the quest for developing the most potent drug. Powerful display technology, combinatorial synthesis or in-silico design often build the foundation to fuel a target-based development project rapidly and efficiently with promising hits.

However, transforming a naïve peptide hit into a quality drug molecule involves many facets of drug discovery and can cause significant bottlenecks during the development cycle. Aside from the apparent collaborative nature required of the various disciplines involved, the creative and flexible nature of the structure–activity relationship (SAR)-driven molecular structure optimization, including sequence optimization, modifications and conjugations, is a critical component that can make or break a program.

In this webinar, the attendees will learn about designing robust syntheses to enhance the SAR process, including which interdisciplinary information is crucial for a successful SAR design. The speaker will also focus on the importance of chemical flexibility, which permits creative design and thorough investigation in SAR studies. They will also share insights into how to optimize an initial peptide of interest into a quality lead molecule using practical examples to illustrate how peptide synthesis design and application can affect the drug development process.

Register for this webinar to gain practical insights and examples on optimizing peptide synthesis and application to navigate bottlenecks and enhance the drug development cycle.

Speaker

William C Blackwell III, Aktis Oncology, RTP, NC

William C Blackwell III, Director of Chemistry, Aktis Oncology, RTP, NC

William C Blackwell III is an experienced Scientist and leader in peptide synthesis and research and development (R&D) with over two decades of expertise. He has a proven track record in various roles, including Associate Director, Principal Scientist and Investigator, contributing to significant advancements in oncology and pharmaceuticals.

Currently, William serves as the Associate Director/Head of Chemistry at Aktis Oncology, based in Research Triangle Park, NC, with a focus on realizing the curative power of alpha radiopharmaceuticals for mainstream cancer care.

Message Presenter

Who Should Attend?

This webinar will appeal to:

  • Synthetic and Medicinal Chemists involved in peptide design and synthesis
  • Analytical Scientists who purify and characterize peptide analogs
  • Project Leaders (peptide drug development)
  • Founders and Scientific Executives in the peptide therapeutic field

What You Will Learn

Attendees will learn about:

  • How to design a robust synthesis to benefit the SAR process
  • Which information from various disciplines in the SAR design ensures success
  • The criticality of chemical flexibility to allow for creative design and thorough investigation of SAR
  • About teamwork and its meaning during a drug discovery program

Xtalks Partner

Gyros Protein Technologies

Gyros Protein Technologies enables peptide and bioanalytical solutions that help scientists increase biomolecule performance and productivity in research, drug discovery, pre-clinical and clinical development, and bioprocess applications. Our low to mid-scale peptide synthesizer platforms are the PurePep® Chorus, Symphony® X, and PurePep® Sonata®+. The PurePep® EasyClean (PEC™) technology complements the PurePep® portfolio with Kits and Services for peptide purification and modification.

Read more...

These solutions and our chemistries deliver uncompromising purity, flexibility, and quality for discovery and pre-clinical studies of simple to complex multifunctional peptides up- and downstream. Proprietary high performance nanoliter-scale immunoassay platforms, Gyrolab® xPand, Gyrolab® xP workstation and Gyrolab xPlore™, are used by scientists in leading pharmaceutical, biotech, CRO, and CMO companies for bioanalytical applications such as pharmacokinetics/pharmacodynamics, immunogenicity, and quantitating bioprocess-related impurities. Our peptide and bioanalytical solutions accelerate your discovery, development, and manufacturing of safer biotherapeutics. Gyros Protein Technologies is part of the Biopharmaceutical Division of Mesa Laboratories, Inc.

Read Less...

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account